Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose

Xenobiotica

Volumn 27, Issue 1, 1997, Pages 59-71

  Waldmeier, F ^a   Flesch, G ^a   Muller P ^b   Winkler, T ^c   Kriemler, H P ^c   Buhlmayer P ^d   De Gasparo, M ^d  

^a Pharma Research   (Switzerland)

^b Human Pharmacology Ciba Geigy   (Switzerland)

^c Spectroscopy Ciba Geigy   (Switzerland)

^d CIBA GEIGY LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; CARBON 14; CGP 71580; DRUG METABOLITE; N (4 HYDROXYVALERYL) N [(2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL)METHYL]VALINE; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; ANIMAL TISSUE; AORTA; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; DRUG URINE LEVEL; FECES; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; ISOTOPE LABELING; LIQUID SCINTILLATION COUNTING; MALE; MASS SPECTROMETRY; NONHUMAN; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; RAT; ULTRAVIOLET SPECTROPHOTOMETRY;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; BIOTRANSFORMATION; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; FLUOROMETRY; HUMANS; MALE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE;

ANIMALIA;

EID: 0031022244     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982597240767     Document Type: Article

References (23)

1. BRADFORD, M. M., 1976, A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254.
2. BROOKMAN, L. J., ROLAN, P. E., BENJAMIN, I. S., PALMER, K. R., WYLD, P. J., LLOYD, P., FLESCH, G., WALDMEIER, F., SIOUFI, A. and MULLINS, F., Pharmacokinetics of valsartan in patients with liver disease. Clinical Pharmacology and Therapeutics (submitted).
3. BRUNNER, L. A., POWELL, M. L., DEGEN, P. and FLESCH, G., 1994, A semiautomated analytical method for the determination of potential antihypertensive agents (CGP 48933 and/or CGP 48369) in human plasma using high-performance liquid chromatography. Laboratory Robotics and Automation, 6, 171-179.
4. BÜHLMAYER, P., FURET, P., CRISCIONE, L., DE GASPARO, M., WHITEBREAD, S., SCHMIDLIN, T., LATTMANN, R. and WOOD, J., 1994, Valsartan, a potent orally active angiotensin II antagonist developed from the structurally new amino acid series. Bioorganic and Medicinal Chemistry Letters, 4, 29-34.
5. BÜHLMAYER, P., OSTERMAYER, F. and SCHMIDLIN, T., Acyl Compounds. European Patent 443983 (Ciba-Geigy).
6. CRISCIONE, L., BRADLEY, W. A., BÜHLMAYER, P., WHITEBREAD, S., GLAZER, R., LLOYD, P., MÜLLER, P. and DE GASPARD, M., 1995, Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovascular Drug Reviews, 13, 230-250.
7. 1-receptor subtype. British Journal of Pharmacology, 110, 761-771.
8. 1 receptors. Regulatory Peptides, 59, 303-311.
9. DE LEAN, A., MUNSON, P. J. and RODBARD, D., 1978, Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curve. American Journal of Physiology, 40, 360-367.
10. FLESCH, G., MÜLLER, P., HELL, F., DEGEN, P., HOWALD, H. and DIETERLE, W., 1996, Absolute oral bioavailability of valsartan in healthy volunteers. Abstract of a poster presented at the 6th European Congress on Biopharmaceutics and Pharmacokinetics, Athens, April 1996. European Journal of Drug Metabolism and Pharmacokinetics (special issue), 34.
11. HELBERGER, J. H., 1936, Über das Verhalten des Lävulinsäurechlorids und der Acetyllävulinsäure bei der Friedel-Craftsschen Reaktion. Annalen, 522, 269-277.
12. HUSKEY, S.-E., MILLER, R. R. and CHIU, S. H. L., 1993, N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys and humans. Drug Metabolism and Disposition, 21, 792-799.
13. KANDA, Y., ARAI, H., ASHIZAWA, T., MORIMOTO, M. and KASAI, M., 1992, New potent mitomycin derivatives: synthesis and antitumor activity of 7,7-(ethylenedioxy)mitomycins. Journal of Medicinal Chemistry, 35, 2781-2786.
14. LO, M.-W., GOLDBERG, M. R., MCCREA, J., LU, H., FURTEK, C. I. and BJORNSSON, T. D., 1995, Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clinical Pharmacology and Therapeutics, 58, 641-649.
15. MEIER, P. J., 1993, Canalicular membrane transport processes. In Hepatic Transport and Bile Secretion, edited by N. Tavoloni and P. D. Berk (New York: Raven), pp. 587-596.
16. MEYER, U. A., AMREIN, R., BALANT, L. P., BERTILSSON, L., EICHELBAUM, M., GUENTERT, T. W., HENAUER, S., JACKSON, P., LAUX, G., MIKKELSEN, H., PECK, C., POLLOCK, B. G., PRIEST, R., SJÖQVIST, F. and DELINI-STULA, A., 1996, Antidepressants and drug-metabolizing enzymes - expert group report. Acta Psychiatrica Scandinavica, 93, 71-79.
17. MUNAFO, A., CHRISTEN, Y., NUSSBERGER, J., SHUM, L. Y., BORLAND, R. M., LEE, R. J., WAEBER, B., BIOLLAZ, J. and BRUNNER, H. R., 1992, Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clinical Pharmacology and Therapeutics, 51, 513-521.
18. OUDE ELFERINK, R. P. J. and JANSEN, P. L. M., 1994, The role of the canalicular multispecific organic anion transporter in the disposal of endo- and xenobiotics. Pharmacology and Therapeutics, 64, 77-97.
19. PARKINSON, A., 1996, An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicologie Pathology, 24, 45-57.
20. STEARNS, R. A., MILLER, R. R., DOSS, G. A., CHAKRAVARTY, P. K., ROSEGAY, A., GATTO, G. J. and CHIU, S. H. L., 1992, The metabolism of DUP-753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metabolism and Disposition, 20, 281-287.
21. STEARNS, R. A., CHAKRAVARTY, P. K., CHEN, R. and CHIU, S. H. L., 1995, Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Drug Metabolism and Disposition, 23, 207-215.
22. 14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. Xenobiotica, 21, 251-261.
23. WHITEBREAD, S., MELE, M., KAMBER, B. and DE GASPARO, M., 1989, Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochemical and Biophysical Research Communications, 163, 284-291.